-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compile | newborn
On December 2, GlaxoSmithKline (GSK) and Vir Biotech announced an update of a study on the preprinted website bioRxiv: Preclinical data showed that the monoclonal antibody sotrovimab targets the new Omicron SARS-CoV-2 variant ( B.
(For details, see: The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2 )
These data were generated by pseudovirus testing of specific individual mutations found in Omicron
Sotrovimab is a SARS-CoV-2 neutralizing monoclonal antibody that can bind to an epitope shared by SARS-CoV-2 and SARS-CoV-1 (the virus that causes SARS).
Sotrovimab targets a conserved epitope of S protein that is unlikely to mutate over time
Reference source: Preclinical data demonstrate sotrovimab retains activity against key Omicron mutations, new SARS-CoV-2 variant